Package Leaflet: Information for the User
EXJADE 90mg Film-Coated Tablets
EXJADE 180mg Film-Coated Tablets
EXJADE 360mg Film-Coated Tablets
deferasirox
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you get. The final part of section 4 includes information on how to report these side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
-Keep this leaflet, you may need to read it again.
1.What is EXJADE and what it is used for
2.What you need to know before taking EXJADE
3.How to take EXJADE
4.Possible side effects
5.Storage of EXJADE
6.Contents of the pack and additional information
What is EXJADE
EXJADE contains an active ingredient called deferasirox. It is aniron chelatorthat is a medication used to eliminate excess iron from the body (also known as iron overload). It captures and eliminates excess iron, which is then excreted mainly in the feces.
For what EXJADE is used
Repeated blood transfusions may be necessary in patients with various types of anemia (for example thalassemia, sickle cell anemia or myelodysplastic syndromes (MDS)).However, repeated blood transfusions can cause an accumulation of excess iron.This is because the blood contains iron and the body does not have a natural way to eliminate excess iron obtained with blood transfusions. In patients with non-transfusion-dependent thalassemic syndromes, iron overload can also appear over time, mainly due to an increase in iron absorption from the diet in response to low blood cell counts.Over time, excess iron can damage important organs such as the liver and heart. Medications callediron chelatorsare used to eliminate excess iron and to reduce the risk of causing damage to organs.
EXJADE is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassemia major, aged 6years or older.
EXJADE is also used to treat chronic iron overload when treatment with deferoxamine is contraindicated or not suitable in patients with beta thalassemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anemia, and in children aged 2to5years.
EXJADE is also used to treat patients aged 10years or older who have iron overload associated with thalassemic syndromes, but who are not dependent on transfusions, when treatment with deferoxamine is contraindicated or not suitable.
Do not take EXJADE
-if you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section6). If this is the case, inform your doctor before takingEXJADE. If you think you may be allergic, consult your doctor.
-if you have moderate or severe kidney disease.
-if you are currently taking any other iron chelating medication.
EXJADE is not recommended
-if you are in an advanced stage of myelodysplastic syndrome (SMD, reduction in blood cell production by the bone marrow) or have advanced cancer.
Warnings and precautions
Consult your doctor or pharmacist before starting to take EXJADE.
-if you have a kidney or liver problem.
-if you have a heart problem due to iron overload.
-if you notice a significant decrease in the amount of urine you eliminate (sign of a kidney problem).
-if you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of a severe allergic reaction, see also section4«Adverse reactions»).
-if you experience a combination of any of the following symptoms: a rash, skin redness, blisters on the lips, eyes, or mouth, skin peeling, high fever, flu-like symptoms, swollen lymph nodes (signs of a severe skin reaction, see also section4«Adverse reactions»).
-if you notice a combination of drowsiness, upper right abdominal pain, yellow or more yellow skin or eyes, and dark urine (signs of liver problems).
-if you notice difficulty thinking, remembering information, or solving problems, or are less conscious or awake or feel drowsy and weak (signs of high ammonia levels in the blood, which may be associated with liver or kidney problems, see also section4«Adverse reactions»).
-if you experience vomiting with blood and/or black stools.
-if you experience frequent abdominal pain, particularly after eating or taking EXJADE.
-if you experience frequent heartburn.
-if you have a low platelet or white blood cell count in your blood test.
-if you have blurred vision.
-if you have diarrhea or vomiting.
If you are in any of these situations, inform your doctor immediately.
Monitoring your treatment with EXJADE
During treatment, regular blood and urine tests will be performed. These tests will monitor the amount of iron in your body (ferritin level in the blood))to observe how EXJADE treatment is working. The tests will also monitor kidney function (creatinine level in the blood, presence of protein in the urine) and liver function (transaminase level in the blood). Your doctor may request a kidney biopsy if they suspect significant renal damage. They may also perform MRI scans to determine the amount of iron in your liver. Your doctor will take these tests into account to decide on the most suitable dose of EXJADE for you and will use these tests to decide when to stop your EXJADE treatment.
Every year, your vision and hearing will be checked during treatment, as a precaution.
Other medicines and EXJADE
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine. This includes, in particular:
-other iron chelating medications, which should not be taken with EXJADE,
-antacids (medicines used to treat heartburn) containing aluminum, which should not be taken at the same time of day as EXJADE,
-ciclosporin (used to prevent organ transplant rejection or for other diseases such as rheumatoid arthritis or atopic dermatitis),
-simvastatin (used to lower cholesterol levels),
-some analgesics or anti-inflammatory medications (e.g. aspirin, ibuprofen, corticosteroids),
-bisphosphonates (used to treat osteoporosis),
-anticoagulants (used to prevent or treat blood clots),
-hormonal contraceptives (medicines for birth control),
-bepridilo, ergotamine (used for heart problems and migraines),
-repaglinida (used to treat diabetes),
-rifampicina (used to treat tuberculosis),
-phenytoin, phenobarbital, carbamazepine (used to treat epilepsy),
-ritonavir (used to treat HIV infection),
-paclitaxel (used to treat cancer),
-theophylline (used to treat respiratory diseases such as asthma),
-clozapina (used to treat psychiatric disorders such as schizophrenia),
-tizanidina (used as a muscle relaxant),
-colestiramina (used to reduce cholesterol levels in the blood).
-busulfan (used as a pre-transplant treatment to destroy the original bone marrow before the transplant),
-midazolam (used to alleviate anxiety and/or sleep disturbances).
Additional tests may be needed to monitor the levels of some of these medications in the blood.
Advanced age (65 years and older)
EXJADE can be used by people over 65 years of age at the same dose as other adults. Older patientsmay experience more adverse effects (especially diarrhea) than younger patients. The doctor should closely monitor any adverse effects that may require a dose adjustment.
Children and adolescents
EXJADE can be used in children and adolescents aged 2 years and older who receive regular blood transfusions and in children and adolescents aged 10 years and older who do not receive regular blood transfusions. As the patient grows, the doctor will adjust the dose.
EXJADE is not recommended for children under 2 years of age.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.
EXJADE treatment is not recommended during pregnancy unless clearly necessary.
If you are currently using a hormonal contraceptive to prevent pregnancy, you should use an additional or different contraceptive (e.g. condom), as EXJADE may reduce the effectiveness of hormonal contraceptives.
EXJADE treatment is not recommended during breastfeeding.
Driving and operating machinery
If you feel dizzy after taking EXJADE, do not drive or operate tools or machinery until you feel normal again.
EXJADE contains sodium
This medicine contains less than 1mmol of sodium (23mg) per coated tablet; it is essentially “sodium-free”.
The treatment with EXJADE will be supervised by a doctor with experience in treating iron overload caused by blood transfusions.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
How much EXJADE to take
The dose of EXJADE is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take per day.
In some countries, deferasirox may also be available as dispersible tablets, manufactured by other manufacturers. If you are switching from these dispersible tablets to EXJADE film-coated tablets, the dose you need to take will change. Your doctor will calculate the dose you need and inform you about how many film-coated tablets to take each day.
When to take EXJADE
Taking EXJADE at the same time every day will also help you remember when to take your tablets.
Patients with difficulty swallowing tablets can crush EXJADE film-coated tablets and take the powder with a soft food, such as yogurt or apple sauce (apple puree). You must consume the entire dose immediately, without saving any for later.
How long to take EXJADE
Continue taking EXJADE every day for the time your doctor tells you.This is a long-term treatment, which may last for months or years. Your doctor will monitor your situation periodically to check that the treatment is having the desired effect (see also section 2: "Monitoring your EXJADE treatment").
If you have doubts about how long you should take EXJADE, consult your doctor.
If you take more EXJADE than you should
If you have taken too much EXJADE, or if someone else has taken your tablets by mistake, contact your doctor or go to the hospital immediately. Show the doctor the packaging of the tablets. You may need urgent medical treatment. You may notice effects such as abdominal pain, diarrhea, nausea, and vomiting, and kidney or liver problems, which could be serious.
If you forget to take EXJADE
If you have forgotten to take a dose, take it as soon as you remember on the same day. Take the next dose according to the normal schedule. Do not take a double dose the next day to make up for the missed dose(s).
If you interrupt EXJADE treatment
Do not stop taking EXJADE unless your doctor tells you to. If you stop taking it, the excess iron will not be eliminated from your body (see also the previous section "How long to take EXJADE").
Like all medicines, this medicine can cause side effects, although not everyone will experience them. Most side effects are mild or moderate and usually disappear after a few days or weeks of treatment.
Some side effects can be serious and require immediate medical attention.
These side effects are rare (may affect up to 1 in 100 people)or very rare (may affect up to 1 in 1,000 people)
Stop taking the medicine and inform your doctor immediately.
Some side effects can be serious.
These side effects are rare
Inform your doctor as soon as possible.
Other side effects
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
swelling, constipation, poor digestion.
If you experience any of these side effects severely, inform your doctor.
Rare (may affect up to 1 in 100 people)
If you experience any of these side effects severely, inform your doctor.
Unknown frequency(cannot be calculated from available data).
Abnormal levels of acid in the blood
Reporting of side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it is apossibleside effect that does not appear in this prospectus.You can also report them directly throughthe national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
after EXP and on the packaging after CAD. The expiration date is the last day of the
month indicated.
pharmacist how to dispose of the packaging and medications that you no longer need. By
doing so, you will help protect the environment.
Composition of EXJADE
The active ingredient is deferasirox.
Each EXJADE film-coated tablet 90 mg contains 90 mg of deferasirox.
Each EXJADE film-coated tablet 180 mg contains 180 mg of deferasirox.
Each EXJADE film-coated tablet 360 mg contains 360 mg of deferasirox.
The other components are microcrystalline cellulose; crospovidone; povidone; magnesium stearate; anhydrous colloidal silica; poloxamer. The film coating contains: hypromellose; titanium dioxide (E171); macrogol (4000); talc; aluminium lake of indigotin (E132).
Appearance of EXJADE and contents of the pack
EXJADE is presented as film-coated tablets. The tablets are oval and biconvex.
Each blister pack contains 30 or 90 film-coated tablets. The multiple pack containing 300 film-coated tablets (10 packs of 30).
Possible commercialisation of only some pack sizes or doses.
Marketing authorisation holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Responsible for manufacturing
Novartis Pharma GmbH
Roonstraße 25
D-90429 Nürnberg
Germany
Novartis Farmacéutica S.A.
Gran Via de les Corts Catalanes 764
08013 Barcelona
Spain
Sandoz S.R.L.
Str. Livezeni nr. 7A
540472 Targu Mures
Romania
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
Luxembourg/Luxemburg Novartis Pharma N.V Tél/Tel: +32 2 246 16 11 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: + 356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 555 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Ελλ?δα Novartis (Hellas) A.E.B.E. Τηλ : +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. T él: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. S í mi : +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 |
Κ?προς Novartis Pharma Services Inc. Τηλ: + 357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija SIA Novartis Baltics Tel: +371 67 887 070 |
Last date of revision of this leaflet:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu .
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.